Skip to main content

Kihara James's Form 4 filing

Acadia Pharmaceuticals Inc (ACAD) · filed Mar 26, 2026

Accession no.
0001816160-26-000003
Filed
Mar 26, 2026
Trade date
Mar 24-26, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $41.9K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kihara JamesCIK 0001816160Officer (PRINCIPAL ACCOUNTING OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 24, 2026Common StockMOption exerciseAcquired+1,627–F1–26,685Direct
Mar 25, 2026Common StockSSaleDisposed−833$21.47−$17,884.5125,852Direct
Mar 25, 2026Common StockMOption exerciseAcquired+2,142–F1–27,994Direct
Mar 26, 2026Common StockSSaleDisposed−1,097$21.65−$23,750.0526,897Direct
Mar 26, 2026Common StockSSaleDisposed−12$21.73−$260.7626,885Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 24, 2026Common StockMOption exerciseDisposed−1,627$0.00$04,883Direct
Mar 25, 2026Common StockMOption exerciseDisposed−2,142$0.00$04,284Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)